A Study of Parsaclisib in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)

Inclusion Criteria:

- Men and women, aged 18 years or older.

- Documented failure to achieve at least PR with, or documented disease progression
after, the most recent treatment regimen.

- Radiographically measurable lymphadenopathy or extranodal lymphoid malignancy.

- Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.

Exclusion Criteria:

- History of central nervous system lymphoma (either primary or metastatic).

- Prior treatment with idelalisib, other selective PI3Kδ inhibitors, or a pan PI3K
inhibitor.

- Allogeneic stem cell transplant within the last 6 months, or autologous stem cell
transplant within the last 3 months before the date of first dose of study treatment.

- Active graft-versus-host disease.

- Liver disease: Subjects positive for hepatitis B surface antigen or hepatitis B core
antibody will be eligible if they are negative for HBV-DNA. Subjects positive for
anti-HCV antibody will be eligible if they are negative for HCV-RNA.